Table 4.

SNEC’s potentially actionable mutations.

Gene	Findings	References	Types of Alterations	Variant Classification of Alterations	Target Drugs (Approved at Least by One Regulatory Agency in Other Cancer Settings)	Principal Treatment Indication (Tumors for Which Are Approved)
SMARCB1	14% (2/14)	Libera et al. 2021. [77]		Deletions, Nonsense	Tazemetostat	Epithelioid Sarcoma
IDH2	11–83% (1/9; 8/39; 5/6) *	Gloss et al. 2021. [70] Riobello et al. 2019 [69]. Dogan et al. 2019. [71]	R172S, R172G, R172M, (R127T), (CNG).	Insertions, deletions	Enasidenib	Acute myeloid leukemia

* Evaluated as SNEC in a cohort of IDH2-mutated sinonasal tumor samples (as numerator number of SNEC and as denominator total number of samples).